ASLAN Pharmaceuticals Pte Ltd In-Licenses Rheumatoid Arthritis Treatment from Almirall

Published: May 21, 2012

by Richard Daverman, PhD

May 21, 2012 -- ASLAN Pharmaceuticals Pte Ltd., the Singapore company that in-licenses drugs for Phase I and II development, has obtained global rights to a DHODH inhibitor, LAS186323, from the Spanish pharma Almirall. LAS186323 is currently in Phase I development for rheumatoid arthritis. Aslan plans to take LAS186323 through a Phase II proof-of-concept trial in the Asia-Pacific region and then license the drug to a global partner for Phase III tests and commercialization. LAS186323 is a novel inhibitor of the DHODH enzyme. More details....

Back to news